Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Abnormal accumulation of β-amyloid (Aβ) in Alzheimer's disease (AD) is associated with prominent brain inflammation. Whereas earlier studies concluded that this inflammation is detrimental, more recent animal data suggest that at least some inflammatory processes may be beneficial and promote Aβ clearance. Consistent with these observations, overproduction of transforming growth factor (TGF)-β1 resulted in a vigorous microglial activation that was accompanied by at least a 50% reduction in Aβ accumulation in human amyloid precursor protein (hAPP) transgenic mice. In a search for inflammatory mediators associated with this reduced pathology, we found that brain levels of C3, the central component of complement and a key inflammatory protein activated in AD, were markedly higher in hAPP/TGF-β1 mice than in hAPP mice. To assess the importance of complement in the pathogenesis of AD-like disease in mice, we inhibited C3 activation by expressing soluble complement receptor-related protein y (sCrry), a complement inhibitor, in the brains of hAPP mice. Aβ deposition was 2- to 3-fold higher in 1-year-old hAPP/sCrry mice than in age-matched hAPP mice and was accompanied by a prominent accumulation of degenerating neurons. These results indicate that complement activation products can protect against Aβ-induced neurotoxicity and may reduce the accumulation or promote the clearance of amyloid and degenerating neurons. These findings provide evidence for a role of complement and innate immune responses in AD-like disease in mice and support the concept that certain inflammatory defense mechanisms in the brain may be beneficial in neurodegenerative disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“other studies have reported that inhibition of different components of complement impaired Aβ phagocytosis, resulting in elevated synapse loss.”
From Microglia in Alzheimer's disease (2017) · cites this paper as [122]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The deficiency of complement factors such as C1q, C3, C3ar1, C5aR, and Cd59, has exacerbated neuropathology in some studies [84–86] and reduced neuropathology in others [87–89].”
From Age, sex and Alzheimer’s disease: a longitudinal study of 3xTg-AD mice reveals sex-specific disease trajectories and inflammatory responses mirrored in postmortem brains from Alzheimer’s patients (2024) · cites this paper as [85]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In the same studies, complement blockade was associated with increased neurodegeneration.”
From Microglia in Alzheimer's disease (2017) · cites this paper as [122]
The cited source says what the claim attributes to it.
In the citing paper
“C3 inhibition enhanced plaque deposition and promoted neurodegeneration in J20 hAPP mice either by over-expression of sCrry (22) or genetic deletion of C3 (21).”
From Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice (2017) · cites this paper as [22]
The cited source says what the claim attributes to it.
In the citing paper
“Further, studies manipulating the complement system have yielded mixed results.”
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
Self-citationImmunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
Cellular Scaling Rules for the Brains of Marsupials: Not as “Primitive” as Expected
Dos Santos, S. E., Porfirio, J., da Cunha, F. B., Manger, P. R., Tavares, W., Pessoa, L., Raghanti, M. A., Sherwood, C. C., & Herculano-Houzel, S. (2017) · Brain, Behavior and Evolution · doi:10.1159/000452856 · Cited by 2,642
NeuN, a neuronal specific nuclear protein in vertebratesxs
Mullen, R. J., Buck, C. R., & Smith, A. M. (1992) · Development · doi:10.1242/dev.116.1.201 · Cited by 2,351
Bard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012
Mucke, L., Masliah, E., Yu, G.-Q., Mallory, M., Rockenstein, E. M., Tatsuno, G., Hu, K., Kholodenko, D., Johnson-Wood, K., & McConlogue, L. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-11-04050.2000 · Cited by 1,856
Self-citationAβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease
Morgan, D., Diamond, D. M., Gottschall, P. E., Ugen, K. E., Dickey, C., Hardy, J., Duff, K., Jantzen, P., DiCarlo, G., Wilcock, D., et al. (2000) · Nature · doi:10.1038/35050116 · Cited by 1,498
Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies
Botto, M., Dell' Agnola, C., Bygrave, A. E., Thompson, E. M., Cook, H. T., Petry, F., Loos, M., Pandolfi, P. P., & Walport, M. J. (1998) · Nature Genetics · doi:10.1038/ng0598-56 · Cited by 1,434
Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease
Janus, C., Pearson, J., McLaurin, J., Mathews, P. M., Jiang, Y., Schmidt, S. D., Chishti, M. A., Horne, P., Heslin, D., French, J., et al. (2000) · Nature · doi:10.1038/35050110 · Cited by 1,431
Inflammation in Neurodegenerative Disease—A Double-Edged Sword
Wyss-Coray, T., & Mucke, L. (2002) · Neuron · doi:10.1016/s0896-6273(02)00794-8 · Cited by 1,235
Self-citation
Research works printed but not linked: 4
- Wyss-Coray, T. & Mucke, L. (2002) Neuron, in press. [DOI] [PubMed]
- Terry R. D., Masliah, E. & Hansen, L. A. (1994) in Alzheimer Disease, eds. Terry, R. D., Katzman, R. & Bick, K. L. (Raven, New York), pp. 179–196.
- Frautschy S. A., Cole, G. M. & Baird, A. (1992) Am. J. Pathol. 140, 1389-1399. [PMC free article] [PubMed] [Google Scholar]
- Holers V. M. (1996) in Clinical Immunology: Principles and Practice, ed. Rich, R. R. (Mosby, St. Louis), pp. 363–391.
Cited by
Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326
“; (ii) in a transgenic mouse model, an increase in C3 expression coincides with a smaller degree of Aβ deposition and neuropatholog”
BackgroundInflammation as a central mechanism in Alzheimer's disease
Kinney, J. W., Bemiller, S. M., Murtishaw, A. S., Leisgang, A. M., Salazar, A. M., & Lamb, B. T. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.06.014 · Cited by 2,253
“Early in AD pathogenesis, the mounted immune response results in clearance of Ab and has been demonstrated to exert positive effects on AD-related pathologies in animal models’ systems [77,119,120].”
BackgroundGenome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease
the European Alzheimer's Disease Initiative Investigators, Lambert, J.-C., Heath, S., Even, G., Campion, D., Sleegers, K., Hiltunen, M., Combarros, O., Zelenika, D., Bullido, M. J., et al. (2009) · Nature Genetics · doi:10.1038/ng.439 · Cited by 2,234
Immune attack: the role of inflammation in Alzheimer disease
Heppner, F. L., Ransohoff, R. M., & Becher, B. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3880 · Cited by 2,134
Microglia in Alzheimer’s disease
Hansen, D. V., Hanson, J. E., & Sheng, M. (2018) · Journal of Cell Biology · doi:10.1083/jcb.201709069 · Cited by 1,935
“Importantly, TREM2-deficient microglia showed reduced uptake of Aβ-lipoprotein complexes in vitro (Yeh et al., 2016) and less evidence of Aβ internalization in vivo (Wang et al., 2016; Yuan et al., 2016).”
BackgroundInfluentialEpidemiology of Alzheimer disease
Reitz, C., Brayne, C., & Mayeux, R. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.2 · Cited by 1,675
Unfolding the role of protein misfolding in neurodegenerative diseases
Soto, C. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1007 · Cited by 1,506
“Inhibiting the activation of the C3 complement component increased neurodegeneration and plaque load in transgenic animal models of A”
BackgroundWyss-Coray (2006) · doi:10.1038/nm1484 · Cited by 1,284
“Overexpression of soluble complement receptor–related protein y (sCrry), which inhibits activation of the central component C3 of the complement cascade, results in increased Aβ load in the brains of APP transgenic mice and in the accumulation of degenerating neurons in the hippocampu”
BackgroundInflammation in Neurodegenerative Disease—A Double-Edged Sword
Wyss-Coray, T., & Mucke, L. (2002) · Neuron · doi:10.1016/s0896-6273(02)00794-8 · Cited by 1,235
Self-citationEpidemiology of Alzheimer Disease
Mayeux, R., & Stern, Y. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006239 · Cited by 1,064
Systemic infections and inflammation affect chronic neurodegeneration
Perry, V. H., Cunningham, C., & Holmes, C. (2007) · Nature Reviews Immunology · doi:10.1038/nri2015 · Cited by 1,027
Inflammation in Alzheimer Disease--A Brief Review of the Basic Science and Clinical Literature
Wyss-Coray, T., & Rogers, J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006346 · Cited by 975
Self-citationYeh, F. L., Wang, Y., Tom, I., Gonzalez, L. C., & Sheng, M. (2016) · Neuron · doi:10.1016/j.neuron.2016.06.015 · Cited by 943
Microglia in Alzheimer's disease
Sarlus, H., & Heneka, M. T. (2017) · Journal of Clinical Investigation · doi:10.1172/jci90606 · Cited by 911
A Review: Inflammatory Process in Alzheimer's Disease, Role of Cytokines
Rubio-Perez, J. M., & Morillas-Ruiz, J. M. (2012) · The Scientific World Journal · doi:10.1100/2012/756357 · Cited by 839
“Complement C3 knockout also aggravated the neuropathology in AD mice [76].”
BackgroundThe Genetics of Alzheimer Disease: Back to the Future
Bertram, L., Lill, C. M., & Tanzi, R. E. (2010) · Neuron · doi:10.1016/j.neuron.2010.10.013 · Cited by 834
Inflammatory processes in Alzheimer's disease
Heneka, M. T., & O'Banion, M. K. (2007) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.11.017 · Cited by 782
“Wyss-Coray and colleagues demonstrated that complement activation can protect against Aβ- induced toxicity and may reduce the accumulation or promote the clearance of senile plaques (Wyss-Coray et al., 2002).”
Does neuroinflammation fan the flame in neurodegenerative diseases?
Frank-Cannon, T. C., Alto, L. T., McAlpine, F. E., & Tansey, M. G. (2009) · Molecular Neurodegeneration · doi:10.1186/1750-1326-4-47 · Cited by 751
“For example, the activation of complement factor C3, the central component of the complement system and a key inflammatory protein may be necessary for plaque clearance by microglia in the ADafflicted brain [56,57].”
Immune activation in brain aging and neurodegeneration: too much or too little?
Lucin, K. M., & Wyss-Coray, T. (2009) · Neuron · doi:10.1016/j.neuron.2009.08.039 · Cited by 679
“APP mouse models where C3 activation is inhibited, via overexpressing soluble complement receptor-related protein y (sCrry), find an increase in Ab deposition and an accumulation of degenerating neurons (Wyss-Coray et al., 2002).”
BackgroundSelf-citationNSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo
Eriksen, J. L., Sagi, S. A., Smith, T. E., Weggen, S., Das, P., McLendon, D. C., Ozols, V. V., Jessing, K. W., Zavitz, K. H., Koo, E. H., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18162 · Cited by 634
“Alternatively, it is possible that under certain circumstances the inflammatory response is beneficial and may actually promote Aβ clearance (9).”
Lian, H., Litvinchuk, A., Chiang, A. C.-A., Aithmitti, N., Jankowsky, J. L., & Zheng, H. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.2117-15.2016 · Cited by 597
“…C3 cleavage products, including C3a, C3b, and iC3b, as well as additional downstream processing products have been shown to mediate A phagocytosis (Wyss-Coray et al., 2002; Maier et al., 2008; Fu et al., 2012), we directly tested the effect of C3a in our system and observed similar results as C3…”
BackgroundResultComplement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice
Shi, Q., Chowdhury, S., Ma, R., Le, K. X., Hong, S., Caldarone, B. J., Stevens, B., & Lemere, C. A. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf6295 · Cited by 593
“Both C3 deficiency and inhibition of C3 convertase by overexpression of sCrry in J20 hAPP transgenicmice led to an age-dependent increase in plaqueburden (21,22).”
BackgroundInfluentialMicroglia-Astrocyte Crosstalk: An Intimate Molecular Conversation
Jha, M. K., Jo, M., Kim, J.-H., & Suk, K. (2019) · The Neuroscientist · doi:10.1177/1073858418783959 · Cited by 579
Casserly, I., & Topol, E. J. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15900-x · Cited by 560
New insights on the role of microglia in synaptic pruning in health and disease
Hong, S., Dissing-Olesen, L., & Stevens, B. (2016) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2015.12.004 · Cited by 557
Cribbs, D. H., Berchtold, N. C., Perreau, V., Coleman, P. D., Rogers, J., Tenner, A. J., & Cotman, C. W. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-179 · Cited by 499
“Innate immune activation can be neuroprotective when it is activated appropriately in response to non-self pathogens and in an acute fashion [4,50-53].”
BackgroundKoenigsknecht-Talboo, J., & Landreth, G. E. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.1808-05.2005 · Cited by 477
“There is clear evidence that microglia routinely survey the brain parenchyma (Nimmerjahn et al., 2005) and act normally through complement-dependent processes to remove A (Wyss-Coray et al., 2002) but are unable to prevent plaque formation in the AD brain.”
BackgroundInfluentialThe amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy
McGeer, P. L., & McGeer, E. G. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1177-7 · Cited by 467
Microglial Phagocytosis of Fibrillar β-Amyloid through a β1Integrin-Dependent Mechanism
Koenigsknecht, J., & Landreth, G. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.2557-04.2004 · Cited by 446
“Wyss-Coray et al. (2002) have recently shed significant new light on this issue by demonstrating that there is a complement-dependent process that is responsible for removing A deposits from the brain.”
BackgroundNeuroinflammatory processes in Alzheimer’s disease
Heneka, M. T., O’Banion, M. K., Terwel, D., & Kummer, M. P. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0438-z · Cited by 433
“However, the complement system may be Janus faced and also provide beneficial action to the brain during AD, Thus, Wyss-Coray et al. (2002) demonstrated that complement activation can protect against Abinduced toxicity and may reduce the accumulation or promote the clearance of senile plaques.”
BackgroundInflammatory process in Alzheimer's Disease
Meraz-Ríos, M. A., Toral-Rios, D., Franco-Bocanegra, D., Villeda-Hernández, J., & Campos-Peña, V. (2013) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2013.00059 · Cited by 427
“…hAPP transgenic model, by the overexpression of the soluble form of the protein related to the complement receptor (sCrry), a 2- to 3-fold increase in Aβ deposits formation was observed in one-year-old hAPP/sCrry mice, which was accompanied by extensive neurodegeneration (Wyss-Coray et al., 2002).”
BackgroundMicroglia and Inflammation in Alzheimers Disease
Mandrekar-Colucci, S., & Landreth, G. E. (2010) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152710791012071 · Cited by 421
“Inhibition of C3 by overexpression of soluble complement receptor related protein y, an inhibitor of complement C3, resulted in a 2-to-3-fold increase in Aβ deposition as well as increased neurodegeneration at 10–12 months of age [114].”
BackgroundVeerhuis, R., Nielsen, H. M., & Tenner, A. J. (2011) · Molecular Immunology · doi:10.1016/j.molimm.2011.04.003 · Cited by 419
“When AD mouse models were made C3 deficient or overexpressing Crry, pathology was enhanced relative to the C3 sufficient mice or to mice with normal levels of Crry suggesting a protective contribution of C3 (Wyss-Coray et al., 2002;Maier et al., 2008).”
BackgroundVarnum, M. M., & Ikezu, T. (2012) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-012-0181-2 · Cited by 394
TLR4 Cross-Talk With NLRP3 Inflammasome and Complement Signaling Pathways in Alzheimer's Disease
Yang, J., Wise, L., & Fukuchi, K.-I. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00724 · Cited by 387
“Inhibition of C3 by overexpressing soluble complement receptor related protein y (sCrry) increases Aβ deposition and neurodegeneration in J20 mice (197).”
BackgroundAlzheimer's Disease and the Amyloid Cascade Hypothesis: A Critical Review
Reitz, C. (2012) · International Journal of Alzheimer's Disease · doi:10.1155/2012/369808 · Cited by 376
“There is evidence that CR1 may contribute to Aβ clearance by complement activation [45].”
BackgroundAlzheimer disease models and human neuropathology: similarities and differences
Duyckaerts, C., Potier, M.-C., & Delatour, B. (2008) · Acta Neuropathologica · doi:10.1007/s00401-007-0312-8 · Cited by 375
“the complement that took place in the Tg mice was useful [345].”
BackgroundLucin, K. M., O’Brien, C. E., Bieri, G., Czirr, E., Mosher, K. I., Abbey, R. J., Mastroeni, D. F., Rogers, J., Spencer, B., Masliah, E., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.06.046 · Cited by 374
“, 1999; Lu and Lemke, 2001) and may be responsible for increased amyloidosis in mouse models of AD (Wyss-Coray et al., 2002).”
Self-citationComplement C3-Deficient Mice Fail to Display Age-Related Hippocampal Decline
Shi, Q., Colodner, K. J., Matousek, S. B., Merry, K., Hong, S., Kenison, J. E., Frost, J. L., Le, K. X., Li, S., Dodart, J.-C., et al. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.1698-15.2015 · Cited by 368
“…uptake and clearance by microglia (Fu et al., 2012), whereas C3 deficiency or C3 inhibition in hAPP-transgenic mice increased A deposition and promoted neurodegeneration (Wyss-Coray et al., 2002; Maier et al., 2008), suggesting that, in some AD-like transgenic mouse models, C3 may be protective.”
BackgroundLuo, R., Su, L.-Y., Li, G., Yang, J., Liu, Q., Yang, L.-X., Zhang, D.-F., Zhou, H., Xu, M., Fan, Y., et al. (2020) · Autophagy · doi:10.1080/15548627.2019.1596488 · Cited by 364
“Genetic defects in different receptors or proteins involved in phagocytosis resulted in neurodegeneration [93,94] and might be responsible for increased amyloidosis in mouse AD models [95].”
BackgroundComplement in neurological disorders and emerging complement-targeted therapeutics
Dalakas, M. C., Alexopoulos, H., & Spaeth, P. J. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0400-0 · Cited by 363
A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease
Hampel, H., Caraci, F., Cuello, A. C., Caruso, G., Nisticò, R., Corbo, M., Baldacci, F., Toschi, N., Garaci, F., Chiesa, P. A., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00456 · Cited by 360
“There is a growing interest on the role of complement and microglia in AD pathology (147).”
BackgroundSankowski, R., Mader, S., & Valdés-Ferrer, S. I. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00028 · Cited by 351
“(Wyss-Coray et al., 2002)”
LPS receptor (CD14): a receptor for phagocytosis of Alzheimer's amyloid peptide
Liu, Y., Walter, S., Stagi, M., Cherny, D., Letiembre, M., Schulz-Schaeffer, W., Heine, H., Penke, B., Neumann, H., & Fassbender, K. (2005) · Brain · doi:10.1093/brain/awh531 · Cited by 349
“Indeed, inhibition of complement 3 in a mouse model of Alzheimer’s disease increased plaque formation and neuro- degeneration (Wyss-Coray et al., 2002).”
BackgroundDoens, D., & Fernández, P. L. (2014) · Journal of Neuroinflammation · doi:10.1186/1742-2094-11-48 · Cited by 348
“Similarly, overexpression of an inhibitor of the complement in a transgenic mouse model of AD triggered higher deposition of Aβ and increased neurodegeneration compared with controls [39].”
BackgroundZipp, F., & Aktas, O. (2006) · Trends in Neurosciences · doi:10.1016/j.tins.2006.07.006 · Cited by 348
Salminen, A., Ojala, J., Kauppinen, A., Kaarniranta, K., & Suuronen, T. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2009.01.001 · Cited by 346
Absence of C1q Leads to Less Neuropathology in Transgenic Mouse Models of Alzheimer's Disease
Fonseca, M. I., Zhou, J., Botto, M., & Tenner, A. J. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.0901-04.2004 · Cited by 345
“J. Neurosci., July 21, 2004 • 24(29):6457– 6465 Fonseca et al. • C1q and Neuropathology in Transgenic AD Mice the increase of A plaques and accumulation of degenerating neurons (Wyss-Coray et al., 2002).”
BackgroundResultInfluentialImmunology and immunotherapy of Alzheimer's disease
Weiner, H. L., & Frenkel, D. (2006) · Nature Reviews Immunology · doi:10.1038/nri1843 · Cited by 335
Chakrabarty, P., Jansen‐West, K., Beccard, A., Ceballos‐Diaz, C., Levites, Y., Verbeeck, C., Zubair, A. C., Dickson, D., Golde, T. E., & Das, P. (2010) · The FASEB Journal · doi:10.1096/fj.09-141754 · Cited by 328
Maier, M., Peng, Y., Jiang, L., Seabrook, T. J., Carroll, M. C., & Lemere, C. A. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.0829-08.2008 · Cited by 323
“Whether the elevation of complement proteins in AD brain is an attempt to protect the brain or a consequence of neuronal damage is unclear, but our results, along with those of Wyss-Coray et al. (2002), suggest that complement C3 may play a protective role in the brain.”
BackgroundResultInfluentialCausative and susceptibility genes for Alzheimer’s disease: a review
Rocchi, A., Pellegrini, S., Siciliano, G., & Murri, L. (2003) · Brain Research Bulletin · doi:10.1016/s0361-9230(03)00067-4 · Cited by 316
Role of complement in neurodegeneration and neuroinflammation
BONIFATI, D., & KISHORE, U. (2007) · Molecular Immunology · doi:10.1016/j.molimm.2006.03.007 · Cited by 313
Neuroinflammatory Markers: Key Indicators in the Pathology of Neurodegenerative Diseases
Rauf, A., Badoni, H., Abu-Izneid, T., Olatunde, A., Rahman, M. M., Painuli, S., Semwal, P., Wilairatana, P., & Mubarak, M. S. (2022) · Molecules · doi:10.3390/molecules27103194 · Cited by 306
“In the early stage of AD pathogenesis, the stimulated immune stimulus leads to Aβ clearance and displays positive action on pathologies linked to AD in animal studies [53,65].”
BackgroundRetractedMicroglia in Alzheimer Disease: Well-Known Targets and New Opportunities
Hemonnot, A.-L., Hua, J., Ulmann, L., & Hirbec, H. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00233 · Cited by 298
Neuroinflammation and microglia: considerations and approaches for neurotoxicity assessment
Harry, G. J., & Kraft, A. D. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.10.1265 · Cited by 295
Microglia actions in Alzheimer's disease
Prokop, S., Miller, K. R., & Heppner, F. L. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1182-x · Cited by 291
Microglia and the brain: Complementary partners in development and disease
Hammond, T. R., Robinton, D., & Stevens, B. (2018) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-100616-060509 · Cited by 288
Complement: a novel factor in basal and ischemia‐induced neurogenesis
Rahpeymai, Y., Hietala, M. A., Wilhelmsson, U., Fotheringham, A., Davies, I., Nilsson, A., Zwirner, J., Wetsel, R. A., Gerard, C., Pekny, M., et al. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601004 · Cited by 279
“…that inhibition of complement activation ag- gravated amyloid plaque formation and neurodegeneration in an experimental model of Alzheimer’s disease (Wyss-Coray et al, 2002), an observation consistent with the involvement of intracerebral complement in brain tissue repair.”
BackgroundComplement System in Neural Synapse Elimination in Development and Disease
Presumey, J., Bialas, A. R., & Carroll, M. C. (2017) · Advances in Immunology · doi:10.1016/bs.ai.2017.06.004 · Cited by 276
Jin, J.-J., Kim, H.-D., Maxwell, J. A., Li, L., & Fukuchi, K.-I. (2008) · Journal of Neuroinflammation · doi:10.1186/1742-2094-5-23 · Cited by 275
“Overexpression of TGF-β1 or IL-1β increased activated microglia and reduced Aβ load in the brains of AD mouse models [24,27].”
Fonseca, M. I., Ager, R. R., Chu, S.-H., Yazan, O., Sanderson, S. D., LaFerla, F. M., Taylor, S. M., Woodruff, T. M., & Tenner, A. J. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901005 · Cited by 268
“While this and other studies (52) have suggested detrimental effects of complement activation in the AD brain, additional investigations have suggested that at least some of the complement factors can decrease the neuropathology in some mouse models of AD (22, 53) or limit the detrimental responses to neurodegenerativ…”
BackgroundInfluentialClusterin: A forgotten player in Alzheimer's disease
Nuutinen, T., Suuronen, T., Kauppinen, A., & Salminen, A. (2009) · Brain Research Reviews · doi:10.1016/j.brainresrev.2009.05.007 · Cited by 267
The significance of neuroinflammation in understanding Alzheimer’s disease
Eikelenboom, P., Veerhuis, R., Scheper, W., Rozemuller, A. J. M., van Gool, W. A., & Hoozemans, J. J. M. (2006) · Journal of Neural Transmission · doi:10.1007/s00702-006-0575-6 · Cited by 262
“2–3 times more Ab than the hAPP littermates (Wyss-Coray et al., 2002).”
BackgroundAging‐dependent changes of microglial cells and their relevance for neurodegenerative disorders
Von Bernhardi, R., Tichauer, J. E., & Eugenín, J. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06537.x · Cited by 258
Inflammation and therapeutic vaccination in CNS diseases
Weiner, H. L., & Selkoe, D. J. (2002) · Nature · doi:10.1038/nature01325 · Cited by 255
“Studies of transgenic mice that overexpress an AD-causing mutant form of human amyloid precursor protein (APP) and develop amyloid deposits have shown, however, that crossing such mice with mice overexpressing a natural inhibitor of complement C3 results in a worsening of Aβ plaque load and more neuronal los”
BackgroundComplement activation in experimental and human temporal lobe epilepsy
Aronica, E., Boer, K., van Vliet, E. A., Redeker, S., Baayen, J. C., Spliet, W. G. M., van Rijen, P. C., Troost, D., Lopes da Silva, F. H., Wadman, W. J., et al. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2007.01.015 · Cited by 226
Alzheimer’s Disease: From Firing Instability to Homeostasis Network Collapse
Frere, S., & Slutsky, I. (2018) · Neuron · doi:10.1016/j.neuron.2017.11.028 · Cited by 237
Wilcock, D. M., DiCarlo, G., Henderson, D., Jackson, J., Clarke, K., Ugen, K. E., Gordon, M. N., & Morgan, D. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-09-03745.2003 · Cited by 232
“Conversely, Wyss-Coray et al. (2002) found that blocking of complement activation with soluble complement receptor-related protein Y overexpression diminished the microglial reaction in APP transgenic mice and led to elevated amyloid loads.”
BackgroundInflammation, anti-inflammatory agents and Alzheimer disease: The last 12 years
McGeer, P. L., Rogers, J., & McGeer, E. G. (2006) · Journal of Alzheimer's Disease · doi:10.3233/jad-2006-9s330 · Cited by 227
“Nevertheless, complement may play a role in clearing of amyloid β in transgenic mice because crossing them with mice genetically engineered to overexpress an inhibitor of complement component C3 results in decreased clearance of the amyloid β deposits [47].”
Brouwers, N., Van Cauwenberghe, C., Engelborghs, S., Lambert, J.-C., Bettens, K., Le Bastard, N., Pasquier, F., Montoya, A. G., Peeters, K., Mattheijssens, M., et al. (2012) · Molecular Psychiatry · doi:10.1038/mp.2011.24 · Cited by 227
“Because CR1 is potentially involved in clearance of fibrillar Aβ peptides from the brain after complement activation and opsonization of Aβ peptides with C3b fragments”
BackgroundVan BEEK, J., ELWARD, K., & GASQUE, P. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb03138.x · Cited by 218
The immunology of neurodegeneration
Czirr, E., & Wyss-Coray, T. (2012) · Journal of Clinical Investigation · doi:10.1172/jci58656 · Cited by 213
Self-citationTherapeutic Inhibition of the Complement System in Diseases of the Central Nervous System
Carpanini, S. M., Torvell, M., & Morgan, B. P. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00362 · Cited by 207
Neuroprotective and neurotoxic properties of glial cells in the pathogenesis of Alzheimer's disease
Farfara, D., Lifshitz, V., & Frenkel, D. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00314.x · Cited by 216
“Moreover, blocking complement activation diminished microglial cell activity in APP-transgenic mice and led to an increase in amyloid loads [31].”
BackgroundInfluentialThe role of the immune system in Alzheimer disease: Etiology and treatment
Jevtic, S., Sengar, A. S., Salter, M. W., & McLaurin, J. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.08.005 · Cited by 215
Microglia in Brain Development, Homeostasis, and Neurodegeneration
Bohlen, C. J., Friedman, B. A., Dejanovic, B., & Sheng, M. (2019) · Annual Review of Genetics · doi:10.1146/annurev-genet-112618-043515 · Cited by 212
Inflammation Induced by Infection Potentiates Tau Pathological Features in Transgenic Mice
Sy, M., Kitazawa, M., Medeiros, R., Whitman, L., Cheng, D., Lane, T. E., & LaFerla, F. M. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.02.012 · Cited by 210
“The deficiency of CCR2, a chemokine receptor, impairs microglia accumulation and increases A deposition in amyloid precursor protein (APP)-transgenic mice, indicating a role for microglia in regulating A accumulation.(22,23) On the other hand, chronic lipopolysaccharide (LPS)–induced neuroinflammation increases intran…”
BackgroundKamphuis, W., Kooijman, L., Schetters, S., Orre, M., & Hol, E. M. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.07.007 · Cited by 209
“Others have shown that a mild degree of microglia activation may in fact limit A β deposition levels, and the presence of CD11c + cells may thus prevent a progression of the in fl ammatory response towards a more detrimental activation level [81 – 85].”
Chakrabarty, P., Ceballos-Diaz, C., Beccard, A., Janus, C., Dickson, D., Golde, T. E., & Das, P. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903382 · Cited by 206
“Ab accumulation, demonstrating a potential beneficial role of complement C3 in Ab removal (61).”
BackgroundVersatility of the complement system in neuroinflammation, neurodegeneration and brain homeostasis
Orsini, F., De Blasio, D., Zangari, R., Zanier, E. R., & De Simoni, M.-G. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00380 · Cited by 201
“Inhibition of C3 convertase formation by the transgenic expression of the sCrry gene, leading to loss of opsonizing effect of C3b, was also shown to result in 2 to 3-fold increase of Aβ accumulation and subsequent neurodegeneration (Wyss-Coray et al., 2002).”
BackgroundInnate Immunity and Neuroinflammation
Shastri, A., Bonifati, D. M., & Kishore, U. (2013) · Mediators of Inflammation · doi:10.1155/2013/342931 · Cited by 199
“Furthermore, inhibition of complement was found to be associated with an increased formation of plaque and neurodegeneration [284].”
BackgroundComplement in the pathogenesis of Alzheimer’s disease
Morgan, B. P. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-017-0662-9 · Cited by 194
“In support of this latter finding, inhibition of complement activation by expression of the C3 convertase regulator soluble Crry in the brain exacerbated amyloid plaque formation and neuronal degeneration in the hAPP model [57].”
BackgroundTau passive immunization inhibits not only tau but also Aβ pathology
Dai, C.-L., Tung, Y. C., Liu, F., Gong, C.-X., & Iqbal, K. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0227-5 · Cited by 187
“Knockout of C3 or overexpression of C3 convertase inhibitor (Crry) was reported to increase the amyloid load burden but to reduce phagocytic microglia [71, 72].”
Exploiting microglial and peripheral immune cell crosstalk to treat Alzheimer’s disease
Dionisio-Santos, D. A., Olschowka, J. A., & O’Banion, M. K. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1453-0 · Cited by 184
“knockout caused increased plaque deposition [62, 63].”
Neuroinflammatory perspectives on the two faces of Alzheimer?s disease
Eikelenboom, P., & van Gool, W. A. (2004) · Journal of Neural Transmission · doi:10.1007/s00702-003-0055-1 · Cited by 182
Fu, H., Liu, B., Frost, J. L., Hong, S., Jin, M., Ostaszewski, B., Shankar, G. M., Costantino, I. M., Carroll, M. C., Mayadas, T. N., et al. (2012) · Glia · doi:10.1002/glia.22331 · Cited by 180
“, 2008) as well as studies from other groups (Choucair-Jaafar et al., 2011; Rogers et al., 2006; Wyss-Coray et al., 2002) have indicated that complement component C3 and complement receptor CR3/Mac-1 might be involved in microglia-mediated uptake and clearance of fAb.”
BackgroundThe Role of Astrocytes and Complement System in Neural Plasticity
Pekny, M., Wilhelmsson, U., Bogestål, Y. R., & Pekna, M. (2007) · International Review of Neurobiology · doi:10.1016/s0074-7742(07)82005-8 · Cited by 173
“Inhibition of complement activation aggravated amyloid plaque formation and neurodegeneration in an experimental model of Alzheimer’s disease (Wyss-Coray et al., 2002) and exposure to C3a induced de novo expression of nerve growth factor, a molecule involved in neuronal growth and survival, in microglial cells in vitr…”
BackgroundThe complement cascade: Yin-Yang in neuroinflammation—neuro-protection and -degeneration
Alexander, J. J., Anderson, A. J., Barnum, S. R., Stevens, B., & Tenner, A. J. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05668.x · Cited by 177
“Complement activation by either pathway could result in the generation of the cleavage peptides C3a and C5a that are known to be chemotactic for microglia and astrocytes (Yao et al. 1990), and indeed microglia and astrocytes localize with b-sheet (fibrillar) amyloid plaques in AD.”
BackgroundSelf-citationMorgan, D., Gordon, M. N., Tan, J., Wilcock, D., & Rojiani, A. M. (2005) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/01.jnen.0000178444.33972.e0 · Cited by 178
“However, when the J20 PDAPP line was crossed with mice overexpressing a complement inhibitor protein (sCRRY), Wyss-Coray et al found increased amyloid deposition and reduced microglia activation at 12 months of age (49).”
BackgroundMethodCR1 is associated with amyloid plaque burden and age‐related cognitive decline
Chibnik, L. B., Shulman, J. M., Leurgans, S. E., Schneider, J. A., Wilson, R. S., Tran, D., Aubin, C., Buchman, A. S., Heward, C. B., Myers, A. J., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22277 · Cited by 174
“Our results are therefore consistent with experiments in vitro and in model organisms that suggest a role for CR1 in clearance of amyloid plaques.(34) These results also establish clear hypotheses relating to the functional consequences of the CR1 risk allele that can now be explored further in a number of systems and…”
ResultCurrent status on Alzheimer disease molecular genetics: from past, to present, to future
Bettens, K., Sleegers, K., & Van Broeckhoven, C. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq142 · Cited by 169
“Complement inhibition of C3 in transgenic mice leads to an increased Ab deposition and neurodegeneration (53), suggesting a protective role of the complement system in AD mice.”
BackgroundImaging Microglial Activation During Neuroinflammation and Alzheimer’s Disease
Venneti, S., Wiley, C. A., & Kofler, J. (2009) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-008-9142-2 · Cited by 170
“Inhibition of complement activation in APP transgenic mice was accompanied by increased Aβ deposition but reduced microglial activation, suggesting that complement-mediated Aβ phagocytosis by microglia is an important mechanism of amyloid clearance (Wyss-Coray et al. 2002).”
BackgroundMultiscale causal networks identify VGF as a key regulator of Alzheimer’s disease
Beckmann, N. D., Lin, W.-J., Wang, M., Cohain, A. T., Charney, A. W., Wang, P., Ma, W., Wang, Y.-C., Jiang, C., Audrain, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17405-z · Cited by 172
Sphingolipids: Critical players in Alzheimer’s disease
van Echten-Deckert, G., & Walter, J. (2012) · Progress in Lipid Research · doi:10.1016/j.plipres.2012.07.001 · Cited by 166
“In AD brains, microglia appear to accumulate in close proximity to Ab plaques and dystrophic neurites [219,220].”
BackgroundNeuroinflammation and regeneration in the early stages of Alzheimer's disease pathology
Hoozemans, J. J. M., Veerhuis, R., Rozemuller, J. M., & Eikelenboom, P. (2006) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2005.11.001 · Cited by 168
“Inhibition of complement activation by expressing soluble complement receptor-related protein, a complement inhibitor, in the brain of hAPP mice lead to a 2–3-fold higher amyloid load and more neuronal loss than in age-matched hAPP mice (Wyss-Coray et al., 2002).”
BackgroundClearance of Amyloid-β Peptides By Microglia and Macrophages: the Issue of What, When and Where
Lai, A. Y., & McLaurin, J. (2012) · Future Neurology · doi:10.2217/fnl.12.6 · Cited by 162
Frenkel, D., Maron, R., Burt, D. S., & Weiner, H. L. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23241 · Cited by 167
Johnson, A. A., Shokhirev, M. N., Wyss-Coray, T., & Lehallier, B. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101070 · Cited by 166
Self-citationDá Mesquita, S., Ferreira, A. C., Sousa, J. C., Correia-Neves, M., Sousa, N., & Marques, F. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.06.014 · Cited by 166
Metadata
- Authors
- Wyss-Coray, T., Yan, F., Lin, A. H.-T., Lambris, J. D., Alexander, J. J., Quigg, R. J., & Masliah, E.
- Affiliations
- Gladstone Institute of Neurological Disease and Department of Neurology, University of California, San Francisco, CA 94141; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104; Department of Medicine, Section of Nephrology, University of Chicago, Chicago, IL 60637; and Departments of Neurosciences and Pathology, University of California at San Diego, La Jolla, CA 92093
- University of California, San Francisco (US)
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2002-07-15
- Volume
- 99
- Issue
- 16
- Pages
- 10837-10842
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC125059
- OpenAlex
- W2047658053
- Cited by
- 446
- References
- 47
- Citations by year
- 2026: 4 · 2025: 13 · 2024: 18 · 2023: 10 · 2022: 13 · 2021: 19 · 2020: 24 · 2019: 21 · 2018: 16 · 2017: 11 · 2016: 13 · 2015: 18 · 2014: 20 · 2013: 17 · 2012: 28
- FWCI
- 9.61
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (1r01ag015871-01a1, AG5131, n01ai30040-13-0-5, 5r29ag010869-05, AI-30040, AG10869, AG15871)
- National Institute on Aging (P50AG005131, AG-5131, AG10869, AG15871)
- National Institute of Allergy and Infectious Diseases (AI30040, N01 AI030040)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK41873, DK58820, R56DK041873, R01DK041873, U24DK058820)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
- Keywords
- Alzheimer's disease, complement activation, complement C3, amyloid-beta deposition, amyloid plaques, neurodegeneration, TGF-β1, microglial activation, innate immunity, amyloid precursor protein transgenic mice, neuroinflammation, amyloid clearance
- MeSH terms
- Alzheimer Disease, Animals, Brain, Complement Activation, Complement C3, Disease Models, Animal, Humans, Mice, Inbred C57BL, Mice, Transgenic, Nerve Degeneration, Neurons, Receptors, Complement, Gene Expression, Amyloid beta-Protein Precursor, Receptors, Complement 3b, Mice, Knockout, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.